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Abstract
We motivate and implement an Artificial Intelligence
(AI) Computer Aided Diagnosis (CAD) framework, to
assist clinicians in the early diagnosis of Mild
Cognitive Impairment (MCI) and Alzheimer’s Disease
(AD). Our framework is based on a Convolutional
Neural Network (CNN) trained and tested on
functional Magnetic Resonance Images datasets. We
contribute to the literature on AI-CAD frameworks for
AD by using a 2D CNN for early diagnosis of MCI.
Contrary to current efforts, we do not attempt to
provide an AI-CAD framework that will replace
clinicians, but one that can work in synergy with them.
Our framework is cheaper and faster as it relies on
small datasets without the need of high-performance
computing infrastructures. Our work contributes to
the literature on digital transformation of healthcare,
health Information Systems, and NeuroIS, while it
opens novel avenues for further research on the topic.

1. Introduction
The digital transformation of healthcare has been a
prominent topic in health information systems (HIS)
the last decade [1]. Artificial intelligence (AI), as part
of the digital transformation toolkit, can enable a more
efficient and effective healthcare provision [2]. One of
the most promising areas of HIS is the application of
AI in assisting medical diagnosis via medical images
[3]. Advances in AI show that such applications can
perform on par with medical experts on diagnosis via
Magnetic Resonance Images (MRI) [4], [5], [6].
Such applications to date, oppose AI to clinicians’
performance [7]. For instance, there have been more
than 20,000 studies on deep learning (DL) methods for
MRI analyses the last ten years, which compare the
performance of AI to clinicians’ performance [8].
Recent work suggests that studies should focus on the
comparison of performance between clinicians using
AI, and their performance without an AI aid [7].
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The recent global pandemic of COVID-19,
however, revealed another urgent need of early disease
diagnosis: the ability to make predictions based on few
cases. The AI Computer-Aided-Diagnosis (CAD)
frameworks to date, are based on large amounts of
data, and require high performance computing (HPC)
infrastructures. To address that lacuna, we propose a
synergistic approach, in which clinicians and scientists
collaborate for faster, cheaper, and more accurate
diagnosis, while the AI-CAD frameworks can rely on
small datasets to make accurate-enough predictions.
Neuro-Information-Systems (NeuroIS), as an
interdisciplinary field that combines cognitive
neuroscience and IS, can address this gap and advance
the theory and practice of HIS [9]. For MRI diagnosis
with AI, this translates to finding which approaches
can provide the most efficient diagnosis and apply
them to assist clinicians with a HIS that compliments
their knowledge and skills. The literature on AI in
healthcare to date, focuses on cancer, the nervous
system, and cardiovascular diseases because these are
the leading causes of disability and mortality [10].
However, a promising frontier where AI can assist
clinicians is Alzheimer’s Disease (AD). Whilst there
was limited progress in the search for treatment to
slow down the progress of AD, last year Biogen
released promising clinical studies for a new drug. To
start treatment in early stages, an early diagnosis is
needed. As it can take up to 20 years before the patient
shows any cognitive decline, it can be difficult to
diagnose AD in early stages. An AI-CAD framework
could assist clinicians in AD diagnosis via MRI.
In this paper, thus, we motivate and implement an
AI-CAD framework for the early diagnosis of Mild
Cognitive Impairment (MCI) and AD to assist
clinicians. By doing so, we contribute to the extant
literature on digital transformation of healthcare [1],
HIS [11], and NeuroIS [12]. The approach that we
proposed in this paper can be extended for the
diagnosis of other diseases, and to further enhance the
digital transformation of healthcare [3].
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2. Background
Table 1. Performance comparison of 2D and 3D methods

AD is the most common reason for dementia,
caused by an accumulation of β-amyloid (Aβ) plaques,
and abnormal amounts of tau proteins in the brain.
This results in synapse loss, where the impulse does
not reach the neurons, and in loss of structure or
function of neurons, including their death, causing
memory impairment and other cognitive problems
[13]. More than 44 million people worldwide suffer
from AD and it is projected to triple by 2050 [14]. AD
has strong impact on patients’ cognitive and physical
functioning, resulting in death [15]. Moreover, there is
also a strong societal and economic impact as global
cost of AD is estimated at more than $818 billion [14].
The recent developments in slowing AD decline
has increased the relevance of its early diagnosis [16],
and MCI plays an important role in the early diagnosis
of AD. MCI is a syndrome where patients have greater
cognitive decline than expected, but it does not affect
their lives [18]. Although some MCI patients remain
stable or return to cognitively normal (CN), there is a
10-15% risk per year of progression to AD [13].
The AD etiology was unknown for the last decade,
and diagnosis relied on neurocognitive tests [18]. This
approach was inefficient and unreliable because AD
could not be distinguished from other dementias. The
development of biomarkers improved the diagnosis of
AD, and many studies have focused on identifying
biomarkers. A common method to diagnose AD is
hippocampus segmentation, which relates to memory
function [19], and its small volume is an AD
biomarker [20]. For a long time, AD diagnosis was
done manually by looking at the brain structure and
size of the hippocampus on MRI, which requires a lot
of practice and precision [21]. There has been an
increasing amount of studies on automated methods
for hippocampus segmentation using machine learning
(ML) and DL with promising results [22], [23].
Hippocampus segmentation for the diagnosis of AD
and MCI, however, requires clinicians’ expertise and
is sensitive to interrater and intra-rater variability [22].
Convolutional Neural Networks (CNN), which is a
successful method for image classification, can
support clinicians in diagnosing AD and MCI. CNN
can significantly improve the performance of image
classification [24], and are becoming increasingly
popular in MRI analysis. Recent studies have showed
that CNN can achieve similar results as a specialist on
classifying MRI of skin cancer patients [5]. Similar
approaches with three-dimensional (3D) as well as
two-dimensional (2D) CNN have also been used for
AD diagnosis with promising results. The filter of a
3D CNN slides along the three dimensions of the input
image, resulting in 3D feature maps, whereas in a 2D

2D CNN

3D CNN

Study
AD

MCI

AD

MCI

Basaia et al. [25]

-

-

.99

.87

Feng et al. [27]

-

-

.95

.86

Korolev et al. [28]

-

-

.80

-

Liu et al. [29]

-

-

.85

-

Liu et al. [30]

-

-

.91

-

Senanayake et al. [31]

-

-

.76

.75

Hon and Khan [32]

.96

-

-

-

Sarraf and Tofighi [33]

.97

-

-

-

Sarraf and Tofighi [34]

.99

-

-

-

Wang et al. [26]

.98

-

-

-

CNN the filter only slides along the height and width
of the input image. Therefore, the latter case results in
2D feature maps with need for less parameters and,
thus, less computational power and time. Most prior
studies used 3D CNN, achieving accuracy up to 99%
for AD diagnosis, and up to 87% for MCI [25], while
others obtained similar results with 2D CNN [26].
A summary of 2D and 3D approaches in the
literature is shown in Table 1. Prior studies, however,
have not applied 2D approaches for detecting MCI.
We will, thus, investigate whether a 2D CNN is
capable of early diagnosing MCI as well as AD.

3. Methodology
Neural networks (NN) are inspired by the human
brain to resolve problems that are simple for humans
but complex for machines [35]. CNN is the most
common NN architecture for image analysis. Fully
connected NN take multiple inputs, and hidden layers
perform calculations on them, while the neurons
connect to each other. Neurons in CNN, however,
connect to others close to them, and all have the same
weight. CNN thus, need fewer parameters than fully
connected NN, which results in small risk of
overfitting, higher accuracy, and faster processing
time. Moreover, in CNN there is no need to transform
images to one-dimensional, a process which can result
in loss of structural information, as CNN learn the
relationships among pixels of input by extracting
representative features with kernel convolutions [13]:
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𝑆(𝑖, 𝑗) = (𝐼 × 𝐾)(𝑖, 𝑗) = + + 𝐼(𝑚, 𝑛)𝐾(𝑖 − 𝑚, 𝑗 − 𝑛)
"

Table 2. Demographic information

!

where 𝐼 is the input and 𝐾 is the kernel; the input
indices are represented by 𝑖 and 𝑗, and the kernel
indices are represented by 𝑚 and 𝑛. A 2D CNN
extracts features by sliding along the height and width
of images, resulting in 2D feature maps. 3D CNN also
slide along the depth of images thus, the kernel does
not have the same depth as the input, resulting in 3D
feature maps. Although previous work established that
3D CNN perform better for patch classifications, the
results between 2D and 3D approaches for whole
image labeling did not differ much [36]. A 3D CNN,
however, is computationally expensive, and, due to the
number of parameters, require more training data [37].
The data used in the preparation of this article were
obtained from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) database (adni.loni.usc.edu). The
ADNI was launched in 2003 as a public-private
partnership. The primary goal of ADNI has been to test
whether MRI, other biological markers, and clinical as
well as neuropsychological assessment can be
combined to measure the progression of MCI and
early AD. The ADNI is separated into 3 studies of 5
years, while the first was prolonged by 2 years under
the name ADNI-GO. In total, 2517 people of ages 5590 participated in the study. The ADNI encourages the
use of their standardized datasets to ensure consistency
in analysis and direct comparison of various methods
among studies. We, therefore, used their two
standardized datasets ‘ADNI1:Complete 2Yr 1.5T’,
and ‘ADNI1:Complete 3Yr 1.5T’, which contain MRI
that have passed quality control assessment [38].
Our dataset consists of 1941 images, distributed in
658 MRI of CN subjects, 411 MRI of AD patients, and
872 MRI of MCI patients. The data come from 99 AD
patients, 148 MCI patients, and a control group of 135
CN subjects. We present the demographic information
of the included subjects in Table 2 to enable
comparison with the samples used in other studies.
The dataset was split into one with CN and AD
subjects (1063 MRI), and one with CN and MCI
subjects (1524 MRI). Since the participants of the
ADNI study returned for more than one check-up, any
patient can have up to 12 MRI, which are not identical
as they are taken at different moments, and every MRI
in the standardized dataset was treated independently.
The standardized datasets are preprocessed,
without noisy MRI, while three more processing steps
have been performed: i) gradwarp correction to correct
inherent nonlinearity of the imaging gradients in MRI
scanners, ii) B1 non-uniformity for a greater
acquisition accuracy of the MRI, and iii) bias field
correction, which can lead to spurious intensity

MCI

AD

CN

Images

891

412

662

Subjects

148

99

135

Gender

105 M / 43 F

52 M / 47 F

66 M / 69 F

μ = 75.59

μ = 75.85

μ = 77.19

σ = 7.40

σ = 7.61

σ = 5.24

Age

variations. Due to the different scanners and
techniques used by the ADNI, the MRI were of
different sizes, and, therefore had to be resized. MRI
with sizes (256, 256, 180), (256, 256, 170), (256, 256,
166), (256, 256, 184) and (192, 192, 160) were resized
to be: (192, 192, 160) with the zoom function of the
Scipy library. In total, 28 MRI from the MCI dataset
and 11 MRI from the AD dataset had opposite
dimensions (e.g. 180, 256, 256), which means
reshaping them would deform them, and, thus, these
MRI were removed from the dataset. Resizing the
MRI results in a different range of pixel values, and,
therefore, to assure that the pixel values of all MRI had
the same range, min-max normalization was applied,
scaling all pixel values between 0 and 1 as follows:
𝑧# =

𝑥# − 𝑚𝑖𝑛(𝑥)
𝑚𝑎𝑥(𝑥) − 𝑚𝑖𝑛(𝑥)

where 𝑥 is the MRI data and 𝑧! the 𝑖th normalized MRI.
The dataset was then split into train set, validation set,
and test set with ratio 60:20:20. After preprocessing,
our AD dataset consisted of 1063 MRI, with 652 CN,
and 411 AD, while the MCI dataset consisted of 1524
MRI, with 872 MCI, and 652 CN subjects.

Figure 1. Convolutional network architecture

Table 3. Convolutional network architecture
Layer

C1

P1

C2

P2

FC1

FC2

FC3

Kernel

3x3

2x2

3x3

2x2

-

-

-

Filter

32

32

64

64

128

64

2
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A NN consists of an input layer, hidden layers, and
an output layer. A CNN has hidden layers divided into
convolution, pooling, activation, and classification
layers. We based our architecture on LeNet-5, which
includes two convolutional layers, two pooling layers,
and two fully connected layers (Figure1 and Table 3).
The Rectified Linear Unit (ReLU) is the most
commonly used activation function in DL because of
its simplicity and performance [39], [40], but when the
activation values are zero, the gradient will be zero
from that point on and, thus, the model will not learn
anymore. This is also referred to as the dying ReLU
problem. As a remedy, we employ the Leaky Rectified
Linear Unit (LReLU) as activation function for all
convolutional layers. LReLU addresses this problem
by allowing for a small non-zero gradient [41]. The
LReLU activation function in our model is defined as:
𝑥,
𝑦(𝑥) = 4
0.01𝑥,

𝑖𝑓𝑥 < 0
𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒

where 𝑥 is the input. A Sigmoid activation function
was applied to the dense layer, which outputs the
probability of the images’ class, with 0 if healthy and
1 if sick (AD or MCI). The Sigmoid function in our
model, with 𝑥 being the input data, is described as:
𝜎(𝑥) =

1
(1 + 𝑒 $% )

The batch size was set to 32, and the optimizer of the
model was Adam [42], with a learning rate of 10-4.
The CNN was built in a Jupyter Notebook using
Python 3.6.4, Tensorflow 2.1.0, and Keras 2.3.1.
TensorFlow is an interface for expressing ML
algorithms, and an implementation for executing them
[43]. Keras is a NN application programming interface
(API), designed to enable fast experimentation with
NN [44]. To load the MRI in NIfTI format, the Nilearn
library was used, which is developed especially for
statistical learning on NeuroImaging data. The scikitlearn and SciPy libraries were used for data
preprocessing. The development, testing, and
application of the model took place on Google Cloud
Console, where we used a storage bucket to store the
datasets, and one compute engine instance with 64
vCPUs and 416 GB of memory to build our model.

positive. F1-score is the harmonic mean between
precision and recall. A NN adjusts its weights to
optimize the loss, which is calculated with the use of
binary cross entropy loss:
' ! ()

𝐶𝐸 = − + 𝑡# 𝑙𝑜𝑔(𝑠# ) = 𝑡& 𝑙𝑜𝑔(𝑠& ) − (1 − 𝑡& )𝑙𝑜𝑔(1 − 𝑠)
#(&

where 𝐶 represents the classes, 𝑠! is the predicted
probability value for class 𝑖, and 𝑡 is the true
probability for that class. Since the data was unevenly
distributed, the accuracy baseline of random guessing
was also calculated. The baseline was calculated with
respect to the class distribution of the dataset. First, we
trained and tested our model on the AD dataset. After
passing the baseline of random guessing on the
training data (>.725) with an accuracy of .910, we
applied the same model on the MCI dataset. The
random guessing baseline for the test dataset of the AD
model was .519 and for the test dataset of the MCI
model was .507. Models’ over-epochs performance is
shown in figure 2 for AD, and in figure 3 for MCI.
The graphs indicate a normal learning curve,
however, as the performance keeps increasing on the
train data, the validation performance flattens, which
implies overfitting. This appears to be stronger on the
MCI dataset than on the AD dataset. Our model
achieved an accuracy of .732 on the AD test-set.
Irrespective of overfitting, the achieved test accuracy
surpasses the random guessing baseline of .519.

Figure 2. Model performance on AD dataset.
Left: Accuracy; Right: Loss

4. Results
The model evaluation was measured in accuracy,
recall, precision, and f1-score. Recall provides
sensitivity information on how many patients were
correctly identified. Precision expresses how many of
the positives that the model returns were actually

Figure 3. Model performance on MCI dataset.
Left: Accuracy; Right: Loss
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Table 5. Comparison of data and accuracy with previous studies
Accuracy
Study

Subjects

Images

Dimensions
AD

MCI

Basaia et al. [25]

645

-

3D

.99

.87

Feng et al. [27]

193

-

3D

.95

.86

Korolev et al. [28]

111

111

3D

.80

-

Liu et al. [29]

193

-

3D

.85

-

Liu et al. [30]

902

-

3D

.91

-

-

322

3D

.76

.75

Hon and Khan [32] *

200

6400

2D

.96

-

Sarraf and Tofighi [33] **

43

367,200

2D

.97

-

Sarraf and Tofighi [34] **

302

62,335

2D

.99

-

Wang et al. [26] **

98

17,738

2D

.98

-

234

1,063

2D

.73

.73

Senanayake et al. [31]

Our

* accuracy before transfer learning = .74
** used fMRI slices independently

The model predicted MCI with accuracy of .734,
passing the random guessing baseline of .507, and
appeared to be overfitting. Table 4 presents the
performance metrics of the models on the test sets.

Table 4. Performance metrics on test data
Data

Loss

Acc.

Prec.

Recall

F1

MRI

AD

1.261

.732

.876

.640

.740

1074

MCI

1.101

.734

.822

.923

.870

1553

The model performs better than chance on both
datasets, with similar loss, accuracy, and precision,
and achieves a better recall on the MCI data as 92.3%
of the MCI patients were correctly identified. The MCI
dataset was larger than the AD one, which may explain
why the performance of MCI is similar to predicting
AD, and for recall even significantly higher.

5. Discussion
Comparing our study to previous ones, we find a
large difference in dataset size (Table 5). Some of the

prior studies only report the number of subjects, but
the number of images can differ from these since one
subject can have up to 12 images in these datasets. As
expected, studies with larger datasets, achieved a
higher accuracy. Moreover, some studies with a 2D
method treated the slices independently, thereby
enlarging the size of their dataset, however, the MRI
is not treated as a whole. We are able, thus, to predict
AD better than chance by .213, and MCI by .227.
We expected the model to perform worse on
detecting MCI than AD, which was not the case.
Although the results for predicting MCI are better than
the AD ones, we cannot conclude that the model
performs better for MCI than for AD, as the MCI
dataset was larger than the AD one. The MCI dataset
had 489 more positive labels than the AD dataset. Our
work, thus, resulted in an AI-CAD framework that can
assist clinicians in the early diagnosis of MCI and AD
with high-enough accuracy, based on a small dataset,
and without the need of HPC infrastructures.

5.1. Implications
The implications of our work are threefold. First,
we contribute to the line of research on using CNN for
AD and MCI diagnosis, by applying a 2D approach.
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Second, whilst AI-CAD frameworks have been
thoroughly studied, they have not been proposed as a
tool for assisting clinicians. Moreover, the existing
approaches are often complicated, and make use of
large amounts of data. Our proposed framework
provides high-enough accuracy to assist clinicians in
their diagnosis for early AD and MCI without the need
of large datasets or HPC infrastructures. Our proposed
approach can also be extended for other diseases, as
well as for cases where time is scarce or limited data
is available. Furthermore, whilst the literature on AICAD frameworks is mostly approached from a
computer science perspective, clinicians have been
shown to lack trust in them [46]. Our work addresses
that lacuna by providing a synergistic approach
between clinicians and scientists, thereby contributing
to the literature on HIS [11] and NeuroIS [12]. The
NeuroIS literature focusses on different disciplines
from theory-focused to design-focused [9]. Our final
contribution, thus, is on bridging these disciplines. The
work we present here, thus, extends current efforts in
the field, and can open avenues for further research.

5.2. Limitations
Our approach has some limitations that should be
acknowledged. First, some preprocessing steps were
not performed because of the required operating
system (OS). An important step in MRI preprocessing
is skull stripping. In this step, the brain tissue is
removed from the image to reduce noise. Commonly
used techniques are the brain extraction tool (BET)
[45], the Brain Surface Extractor (BSE) [47], and the
Robust Brain Extraction (ROBEX) [48]. The
automated methods in Python for these techniques,
however, are only useable under Unix. Due to the used
OS, skull stripping could not be applied to all images
in the dataset and was therefore omitted. As noise in
the data can lead to unexpected results in classification
due to false feature extraction, it is expected that
skipping this step has direct consequences to the
performance of the CNN. Skull stripping (BET2 in
particular) leads to a better segmentation [49], it is
however difficult to say how large the impact is for
classification tasks. Second, our model showed
overfitting, which means that it includes more terms or
uses more complicated approaches than necessary
[50]. Regularization can control overfitting and dropout regularization is a commonly used approach
because it is computationally inexpensive, and it
prevents co-adaptation among feature map units [37].
We added dropout regularization to our model, and
although it performed slightly better on training and
validation data, it performed worse on the test data.
For that reason, we omitted dropout regularization.

5.3. Future Research
Our work offers a faster and cheaper method for
classifying MRI, as resources can be saved from not
having to acquire computational power. We proposed
a 2D approach for MCI and AD detection because the
3D one has drawbacks related to its computational
requirements. As a next step of our research project,
we intend to replicate the existing 3D approaches in
the literature, and compare their execution time with
the one of our model’s, on the same computational
infrastructure. Such a comparison of execution time
will further illustrate the merits of our proposed
approach before proposing it for testing and
implementation to the broader healthcare system.
Whilst we will further develop the accuracy of the
model before proceeding, our next step is to evaluate
the performance of clinicians using our AI-CAD
framework, and their performance without the AI aid.
For this step, we have already established
collaboration with hospitals and clinics that have
geriatric units specializing in AD and MCI, and we are
ready to proceed with a pilot phase. Such collaboration
will provide us with unique datasets to further enhance
the externality of our model, as most studies using
CNN on AD and MCI are based on the ADNI datasets.
Moreover, quantum computing (QC) is a new
paradigm that could offer a solution to the challenge
we address. The field of quantum DL provides
innovative algorithms that offer significant speedups
over the classical DL approaches [51]. We aim, thus,
to further develop an AI-CAD framework with a
Quantum CNN (QCNN). In classical computing a bit
can either be |0⟩ or |1⟩; a qubit in QC can be |0⟩, |1⟩,
or in a superposition state 𝛼|0⟩ + 𝛽|1⟩ with
amplitudes (𝛼, 𝛽) ∈ 𝐶 such that |𝛼| " + |𝛽| " = 1. In
classical computing, processes are executed in
sequence, while in QC processes run simultaneously
further optimizing, thus, the total run time. Moreover,
QCNN do not suffer from the issue of causal
asymmetry that can affects classic CNN [52]. Should
the QC paradigm become more easily accessible in the
coming years, such an approach can provide clinicians
with fast access to predictive models to address urgent
situations, as well as the lack of large datasets.

6. Conclusion
Prior studies have used CNN to diagnose MCI and
AD, most of which applied 3D approached, with
promising results. 3D CNN, however, has drawbacks
that relate to needs for HPC infrastructures. Other
studies have focused on detecting AD with a 2D CNN,
achieving similar results as the 3D approach. Despite
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the relevance of detecting MCI, prior studies did not
investigate how these methods perform on detecting
MCI. Our main goal was to determine whether a 2D
CNN can be used to diagnose AD and MCI. Our work
resulted in an AI-CAD framework that can assist
clinicians in the early diagnosis of MCI and AD with
high-enough accuracy, based on a small dataset, and
without the need of HPC infrastructures. Our next step
will be to evaluate the performance of clinicians with
and without the use of our AI-CAD framework. As a
follow-up study, we intent to develop an AI-CAD
framework with a QCNN, which could provide
clinicians with fast access to predictive models to
address urgent situations and the lack of large datasets.
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